ALEMBIC LIMITED Alembic Limited Stock NSE India S.E.
Equities
ALEMBICLTD
INE426A01027
Real Estate Development & Operations
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.35 INR | -0.42% |
|
+1.78% | +4.25% |
| Apr. 18 | Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3% | MT |
| Apr. 02 | Alembic Pharmaceuticals Gets US FDA Tentative Nod for Generic Breast Cancer Treatment | MT |
| Sales 2022 | 782M 9.38M | Sales 2023 | 1.27B 15.26M | Capitalization | 15.22B 183M |
|---|---|---|---|---|---|
| Net income 2022 | 2.22B 26.64M | Net income 2023 | 1.91B 22.86M | EV / Sales 2022 | 23.4 x |
| Net cash position 2022 | 270M 3.24M | Net cash position 2023 | 464M 5.56M | EV / Sales 2023 | 11.6 x |
| P/E ratio 2022 |
8.37
x | P/E ratio 2023 |
7.99
x | Employees | 271 |
| Yield 2022 |
2.49% | Yield 2023 |
3.71% | Free-Float | 27.91% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.42% | ||
| 1 week | +1.78% | ||
| Current month | +13.06% | ||
| 1 month | +16.70% | ||
| 3 months | +1.23% | ||
| 6 months | +18.75% | ||
| Current year | +4.25% |
1 week
90.95
97.00
1 month
80.90100.00
Current year
78.10107.65
1 year
61.20107.65
3 years
55.20143.30
5 years
24.80143.30
10 years
16.55143.30
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 88-07-01 | |
Rasesh J. Shah
DFI | Director of Finance/CFO | - | 14-08-12 |
| Chairman | 76 | 67-08-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 67-08-19 | |
| Chief Executive Officer | 69 | 88-07-01 | |
| Director/Board Member | 44 | 13-04-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 94.35 | -0.42% | 579,768 |
| 24-04-25 | 94.75 | -1.04% | 460,484 |
| 24-04-24 | 95.75 | +2.08% | 600,677 |
| 24-04-23 | 93.8 | +1.96% | 618,293 |
| 24-04-22 | 92 | -0.76% | 722,825 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT
More quotes
Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.
Calendar
2024-05-15
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +36.16% | 27.29B | |
| -13.74% | 26.65B | |
| +25.00% | 26.56B | |
| -0.71% | 23.73B | |
| +44.49% | 22.46B | |
| +2.78% | 19.61B | |
| +1.45% | 18.04B | |
| +28.54% | 16.12B | |
| -14.80% | 14.69B |
- Stock Market
- Equities
- 506235 Stock
- ALEMBICLTD Stock
